Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2007-04-03
2007-04-03
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S308000, C514S012200
Reexamination Certificate
active
10450042
ABSTRACT:
The present invention encompasses a GLP-1analog and compositions and formulations thereof useful for the treatment of hyperglycemia and other various diseases and conditions in mammals.
REFERENCES:
patent: 4347374 (1982-08-01), Kollonitsch et al.
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5977071 (1999-11-01), Galloway et al.
patent: 6133235 (2000-10-01), Galloway et al.
patent: 6284727 (2001-09-01), Kim et al.
patent: 6388053 (2002-05-01), Galloway et al.
patent: 6410513 (2002-06-01), Galloway et al.
patent: 2004/0053370 (2004-03-01), Glaesner et al.
patent: 0 619 322 (1994-02-01), None
patent: 0 733 644 (1996-09-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 92/18531 (1992-10-01), None
patent: WO 93/18786 (1993-09-01), None
patent: WO 95 05848 (1995-03-01), None
patent: WO 93/25579 (1995-12-01), None
patent: WO 87 06941 (1997-11-01), None
patent: WO 99 30731 (1999-06-01), None
patent: WO 00 01727 (2000-01-01), None
patent: WO 02 10195 (2002-02-01), None
Altman, J., et al., “An Improved Synthesis of L-Homhistidine,” Synthetic Commun., 19 (11 & 12) : 2069-2076, 1989.
Ananthanarayanan, V.S., et al. “Ca2+Binding and Ionophoretic Properties of Peptide Hormones: Studies on Insulin and Glucagon,” Molecular Biology Cell (Supp) 3, 250A, 1992.
Clark, B. A., et al, “Effect of Glucose, Insulin, and Hypertonicity on Atrial Natriuretic Peptide Levels in Man.” Database Medline Online, US National Library of Medicine, Bethesda, MD, XP002214279, Clinical and Experimental, vol. 42, No. 2, Feb. 1993 (1193-02), pp. 224-228, abstract.
Epand, R.M., “Cation-Induced Conformational Change in Glucagon,” Molecular Pharmacology, 22:105-108, 1982.
Galloway, J.A., “Treatment of NIDDM With Insulin Agonists or Substitutes,” Diabetes Care, 13: 1209-1239, 1990.
Galloway, J.A., “Insulin Agonist Therapy: A Challenge for the 1990s,” Clinical Therapeutics, 12:460-472, 1990.
Gutniak, M, et al., “Antidiabetogenic Effect of Glucagon-Like Peptide-I (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus,” New England Journal of Medicine, 326 (20) : 1316-1322, 1992.
“Handbook of Experimental Pharmacology,” Springer-Verlag, Hasselblatt, et al., (Eds.), 32 (2) :729-777, 1975.
Holz, G. G., et al., Pancreatic Beta-Cells Are Rendered Glucose-Competent by the Insulinotropic Hormone Glucagon-Like Peptide 1(7-37) , Nature, 361:362-365, 1993.
Ishikawa, Hirokazu, et al, “Large-Scale Preparation of Recombinant Human Calcitonin from a Multimeric Fusion Protein Produced inEscherichia coli” XP 002214281 & Journal of Bioscience and Bioengineering, 87 (3), 296-301, 1999, abstract.
Komatsu, R., et al., “Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide 1-(7-36)-Amide,” Diabetes, 38:902-905, 1989.
Levine-Pinto, H. et al., “Specific and Direct Fluorinatii Histidine-Containing Peptide,” Biochemical, Biophysical Research Communications, 103(4) :1121-1130, 1981.
Mentlein, R., et al., “Dipeptidyl-peptidase IV Hydrolyses Gastric Inhibitory Polypeptide, Glucagon-like Peptide-1 (7-36Amide, Peptide Histidine Methionine and is Responsible for their Degradation in Human Serum,” Eur. J. Biochem, 214:829-835, 1993.
Mojsov, S., “Structural Requirements for Biological Activity of Glucagon-like Peptide-I,” Int. J. Peptide Protein Res., 40:333-343, 1989.
Nauck, M.A., et al., “Preserved Incretin Activity of Glucagon-like Peptide 1[7-36 Amide] but Not of Synthetic Human Gastric Inhibitory Polypeptide in Patients with Type-2 Diabetes Mellitus,” J. Clinical Invest., 91:301-307, 1993.
Nauck, M.A., et al., Normalization of Fasting Hyper-glyeaemia by Exogenous Glucagon-like Peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) Diabetic Patients Diabetologia, 36:741-744, 1993.
O'Donnell, J.J., et al., Synthesis of A-Methylhistidine By Catalytic Phase-Transfer Alkylations, Synthetic Communication, 19 (7 & 8) :1157-1165, 1989.
Orskov, C., “Glucagon-Like Peptide-1: A New Hormone of the Entero-insular Axis,” Diabetologia, 35: 701-711, 1992.
Orskov, C., et al., “Complete Sequences of Glucagon-like Peptide- 1 from Human and Pig Small Intestine,” Journal of Biological Chemistry, 264 (22) :12826-12829, 1989.
Owa, T., et al., “An Efficient Synthesis of Erythro-β-Hydroxy-L-histidine, the Pivotal Amino Acid of Bleomycin-Fe (II) -02Complex1,” Chem. Letters: 873-874, 1988.
Pridal, Lone, et al, “Absorption of Glucagon-like Peptide-1 Can Be Protracted by Zinc or Protamine” XP 002214282; International Journal of Pharmaceuticals, 136:53-59, 1996.
Suzuki, S, et al, “Comparison of the Effects of Various Carboxyl-Terminal and Amino-Terminal Fragment Peptides of Glucagon-Like Peptide-1 on Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas.” XP 002214280 & Endocrinology, vol. 125, No. 6, 3109-3114, 1989.
Thorens, B., et al., “Perspectives in Diabetes: Glucagon-Like Peptide-1 and the Control of Insulin Secretion in the Normal State and in NIDDM,” Diabetes, 42:1219-1225, 1993.
DiMarchi Richard Dennis
Glaesner Wolfgang
Millican, Jr. Rohn Lee
Cox Gregory A.
Eli Lilly and Company
Lukton David
Stewart Mark J.
LandOfFree
Amidated glucagon-like peptide-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amidated glucagon-like peptide-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amidated glucagon-like peptide-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3723529